Notably, embryonic cardiomyocytes lacking LONP1 exhibit accumulation of abnormal mitochondrial protein aggregates, which subsequently activate the phosphorylation of eukaryotic initiation factor 2 (eIF2)-transcription factor 4 (ATF4) signaling axis to trigger compensatory metabolic remodeling: ATF4 upregulates the expression of glucose transporter 1 (GLUT1) to enhance glycolytic energy production
Simon Medicaid GLP-1 Coverage and Prescribing Patterns Studying how state Medicaid coverage of GLP-1s for weight management affects prescribing and spending, using staggered adoption across states, from Coady Wing, Wei-Lun Lo, Maddie Potter, Tarik Yuce, Alberto Ortega, John Cawley, Thuy D
PMID: 22 CaliT.BayerE
proportion of participants who achieved body weight reduction thresholds and fat mass reduction thresholds at weeks 48 and 72
Notably, a Business Group on Health survey fielded earlier this year found that 87% of employers expect the availability of oral medications to increase demand for GLP-1s, while only 9% predict a price drop
